are compound pharmacies stopping semaglutide Hims & Hers stock falls 25% as FDA curtails compounded GLP-1s Compound semaglutide not working: why

GLP-1s have moved from social media, family group chats, and dinner-table discussions to clinical conversations to employer benefits meetings, almost overnight

This benefit is likely mediated by the Nrf2-dependent reduction of endothelial ROS and the stabilization of vascular barriers

Recently Novo Nordisk announced the initiation of REDEFINE 4, a phase 3 trial comparing CagriSema 2.4 mg with Lillys Zepbound 15 mg evaluating weight loss after 72 weeks in 800 obese patients non-diabetic and is expected to be completed by October 2025 (NCT06131437)

Emerging medications like retatrutide may eventually surpass all current options, and the precise dosing comparisons between medications help clinicians optimize individual treatment plans

Is a 57 bpm Increase Clinically Significant

Reducing inflammation may reduce plaque in the arteries, and thats where GLP-1s come in